Loading
Ryan Sullivan is a melanoma trialist and a leading voice on managing immunotherapy side effects.
Ryan J. Sullivan is Associate Director of the Melanoma Program at Massachusetts General Hospital Cancer Center. He is a melanoma trialist and a leading voice on managing the side effects of immunotherapy, having co-authored society guidelines on immune-related adverse events. His selected paper is the ASCO guideline update on managing immune-related adverse events in patients treated with immune checkpoint inhibitors. He leads melanoma clinical trials at MGH and studies how to sequence targeted and immune therapy, including DREAMseq-style questions.
| Title | Journal | Year |
|---|---|---|
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update | Journal of Clinical Oncology | 2021 |
| KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery | The Lancet | 2024 |
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Melanoma, Immune checkpoint inhibitors.
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Melanoma, Immune checkpoint inhibitors.
Shares Massachusetts General Hospital Cancer Center, Melanoma.
Shares Massachusetts General Hospital Cancer Center, Immune checkpoint inhibitors.
Shares Massachusetts General Hospital Cancer Center, Melanoma.
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Melanoma.
Shares Massachusetts General Hospital Cancer Center, Immune checkpoint inhibitors.
Shares Massachusetts General Hospital Cancer Center, Immune checkpoint inhibitors.